Montpellier, July 20, 2022 at 8:00 a.m. – MEDESIS PHARMA, a pharmaceutical biotechnology company developing drug candidates based on its proprietary Aonys® technology for the administration of active ingredients in nano micelles by oral route, announces the decision of the AFM-Téléthon to contribute up to 300,000 euros over 24 months to contribute to the first phases of preclinical development of its treatment for Huntington’s disease.
The AFM-Téléthon, French Association against Myopathies, has decided to participate in the financing of the preclinical program developed by MEDESIS PHARMA
The Board of Directors of AFM-Téléthon, at its meeting of July 7, 2022, gave an agreement in principle for the financing of the NanosiRNA-HD project: “Use of NanosiRNA for the treatment of Huntington’s disease” for a duration of 24 months and a total amount of 300,000 euros excluding tax, corresponding to 1/3 of the total cost of preclinical development.